C5AR1 and Alzheimer disease: Pharmacological inhibition of C5aR1 using the antagonist PMX205 has consistently demonstrated therapeutic benefit in transgenic AD models such as Tg2576 and Arctic48, where it reduced amyloid burden, gliosis, and cognitive decline [111, 237].